Heart failure: Future treatment approaches

American Journal of Hypertension

Volumn 13, Issue 5 II SUPPL., 2000, Pages

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Heart failure; Valsartan

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRADYKININ; CANDESARTAN HEXETIL; CAPTOPRIL; CARDIAC GLYCOSIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; LOSARTAN; METOPROLOL; MILRINONE; MOXONIDINE; NITRATE; PLACEBO; SPIRONOLACTONE; VALSARTAN; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; HEART FAILURE; HORMONE INHIBITION; HOSPITALIZATION; HUMAN; MORTALITY; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROGNOSIS; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; VASODILATATION;

EID: 0034034874     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(00)00271-5     Document Type: Article

References (25)

1. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
3. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
5. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
6. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
8. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
9. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
10. van Zwieten PA: Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens 1999;21:859-873.
11. Cohn JN: The MOXCON Study. European Society of Cardiology Hot Line Sessions, Barcelona, Spain, 1999.
12. Webb DJ, Strachan FE: Clinical experience with endothelin antagonists. Am J Hypertens 1998;11:71S-79S.
13. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT: Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 1999;99:1984-1990.
14. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820.
15. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJJ, Ritsema van Eck HJ, Boomsma F, Derkx FHM, Schalekamp MADH: Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-812.
16. Urata H, Nishimura H, Ganten D: Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16(suppl N):79-85.
17. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
18. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-2048.
19. Gallagher AM, Yu H, Printz MP: Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998;32:84-88.
20. de Gasparo M, Levens N: Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 1998;82:257-271.
21. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of Elite Study Investigators: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
22. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-154.
23. Hughes S: Losartan disappoints in ELITE-2. SCRIP World Pharmaceut News 1999;2489:19.
24. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN, for the Vasodilator Heart Failure Trial (V-HeFT) Study Group: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-2664.
25. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999;5:155-160.